83,889 Shares in Viking Therapeutics, Inc. (NASDAQ:VKTX) Bought by Quinn Opportunity Partners LLC

Quinn Opportunity Partners LLC purchased a new stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 83,889 shares of the biotechnology company's stock, valued at approximately $3,376,000. Quinn Opportunity Partners LLC owned approximately 0.08% of Viking Therapeutics as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Cahill Wealth Management LLC boosted its position in Viking Therapeutics by 11.0% during the 4th quarter. Cahill Wealth Management LLC now owns 15,295 shares of the biotechnology company's stock worth $615,000 after purchasing an additional 1,515 shares during the period. Kennedy Capital Management LLC boosted its position in shares of Viking Therapeutics by 2.5% in the fourth quarter. Kennedy Capital Management LLC now owns 43,019 shares of the biotechnology company's stock worth $1,731,000 after buying an additional 1,058 shares during the period. Treasurer of the State of North Carolina grew its stake in shares of Viking Therapeutics by 1.7% in the fourth quarter. Treasurer of the State of North Carolina now owns 46,730 shares of the biotechnology company's stock valued at $1,880,000 after buying an additional 780 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Viking Therapeutics in the fourth quarter valued at about $24,888,000. Finally, Advisory Services Network LLC raised its holdings in shares of Viking Therapeutics by 36.4% during the 4th quarter. Advisory Services Network LLC now owns 34,470 shares of the biotechnology company's stock valued at $1,387,000 after buying an additional 9,198 shares during the period. 76.03% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Insider Activity at Viking Therapeutics

In related news, Director Sarah Kathryn Rouan acquired 1,240 shares of Viking Therapeutics stock in a transaction that occurred on Monday, March 31st. The stock was acquired at an average price of $24.15 per share, with a total value of $29,946.00. Following the completion of the acquisition, the director now directly owns 1,240 shares of the company's stock, valued at $29,946. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.70% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have issued reports on VKTX shares. Citigroup initiated coverage on shares of Viking Therapeutics in a research report on Friday, February 7th. They issued a "neutral" rating and a $38.00 price objective for the company. The Goldman Sachs Group initiated coverage on Viking Therapeutics in a research note on Tuesday, April 8th. They issued a "neutral" rating and a $30.00 price target on the stock. Raymond James lifted their price objective on Viking Therapeutics from $122.00 to $125.00 and gave the stock a "strong-buy" rating in a report on Thursday, February 6th. HC Wainwright reiterated a "buy" rating and set a $102.00 target price on shares of Viking Therapeutics in a research note on Wednesday, March 26th. Finally, Piper Sandler dropped their price target on shares of Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating for the company in a research note on Thursday, February 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Viking Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $89.75.

Viking Therapeutics Stock Up 10.6 %

VKTX stock traded up $2.35 during midday trading on Monday, reaching $24.57. The company had a trading volume of 9,146,954 shares, compared to its average volume of 4,007,879. The firm has a market capitalization of $2.76 billion, a PE ratio of -24.57 and a beta of 0.84. The stock has a 50 day moving average price of $27.71 and a 200 day moving average price of $43.07. Viking Therapeutics, Inc. has a fifty-two week low of $18.92 and a fifty-two week high of $81.86.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.05). During the same period in the previous year, the company posted ($0.25) earnings per share. Research analysts predict that Viking Therapeutics, Inc. will post -1.56 EPS for the current year.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.